229 related articles for article (PubMed ID: 24488785)
21. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
Ohnishi K
Int J Clin Oncol; 2007 Oct; 12(5):313-7. PubMed ID: 17929112
[TBL] [Abstract][Full Text] [Related]
22. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
23. Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
Petit A; Delaune A; Falluel-Morel A; Goullé JP; Vannier JP; Dubus I; Vasse M
Pharmacol Res; 2013 Nov; 77():11-21. PubMed ID: 24004656
[TBL] [Abstract][Full Text] [Related]
24. The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic.
Andre C; Guillemin MC; Zhu J; Koken MH; Quignon F; Herve L; Chelbi-Alix MK; Dhumeaux D; Wang ZY; Degos L; Chen Z; de The H
Exp Cell Res; 1996 Dec; 229(2):253-60. PubMed ID: 8986606
[TBL] [Abstract][Full Text] [Related]
25. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
[TBL] [Abstract][Full Text] [Related]
26. Involvement of PML-I in reformation of PML nuclear bodies in acute promyelocytic leukemia cells by leptomycin B.
Wang C; Su L; Shao YM; Chen WZ; Bu N; Hao R; Ma LY; Hussain L; Lu XY; Wang QQ; Naranmandura H
Toxicol Appl Pharmacol; 2019 Dec; 384():114775. PubMed ID: 31669778
[TBL] [Abstract][Full Text] [Related]
27. Medicine. Poisonous contacts.
Kogan SC
Science; 2010 Apr; 328(5975):184-5. PubMed ID: 20378808
[No Abstract] [Full Text] [Related]
28. Role of the promyelocytic leukaemia protein in cell death regulation.
Salomoni P; Dvorkina M; Michod D
Cell Death Dis; 2012 Jan; 3(1):e247. PubMed ID: 22237204
[TBL] [Abstract][Full Text] [Related]
29. Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond.
Chen SJ; Zhou GB
IUBMB Life; 2012 Aug; 64(8):671-5. PubMed ID: 22714999
[TBL] [Abstract][Full Text] [Related]
30. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
Wang ZG; Rivi R; Delva L; König A; Scheinberg DA; Gambacorti-Passerini C; Gabrilove JL; Warrell RP; Pandolfi PP
Blood; 1998 Sep; 92(5):1497-504. PubMed ID: 9716575
[TBL] [Abstract][Full Text] [Related]
31. PML nuclear bodies mediate the therapeutic response of APL cells.
Cancer Discov; 2014 Mar; 4(3):OF20. PubMed ID: 24596215
[TBL] [Abstract][Full Text] [Related]
32. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
[TBL] [Abstract][Full Text] [Related]
33. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein.
Nervi C; Ferrara FF; Fanelli M; Rippo MR; Tomassini B; Ferrucci PF; Ruthardt M; Gelmetti V; Gambacorti-Passerini C; Diverio D; Grignani F; Pelicci PG; Testi R
Blood; 1998 Oct; 92(7):2244-51. PubMed ID: 9746761
[TBL] [Abstract][Full Text] [Related]
34. PML targeting eradicates quiescent leukaemia-initiating cells.
Ito K; Bernardi R; Morotti A; Matsuoka S; Saglio G; Ikeda Y; Rosenblatt J; Avigan DE; Teruya-Feldstein J; Pandolfi PP
Nature; 2008 Jun; 453(7198):1072-8. PubMed ID: 18469801
[TBL] [Abstract][Full Text] [Related]
35. The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.
Rabellino A; Carter B; Konstantinidou G; Wu SY; Rimessi A; Byers LA; Heymach JV; Girard L; Chiang CM; Teruya-Feldstein J; Scaglioni PP
Cancer Res; 2012 May; 72(9):2275-84. PubMed ID: 22406621
[TBL] [Abstract][Full Text] [Related]
36. Guest editorial: acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia.
Komatsu N
Int J Hematol; 2014 Jul; 100(1):16-7. PubMed ID: 24912657
[No Abstract] [Full Text] [Related]
37. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.
Chen GQ; Zhu J; Shi XG; Ni JH; Zhong HJ; Si GY; Jin XL; Tang W; Li XS; Xong SM; Shen ZX; Sun GL; Ma J; Zhang P; Zhang TD; Gazin C; Naoe T; Chen SJ; Wang ZY; Chen Z
Blood; 1996 Aug; 88(3):1052-61. PubMed ID: 8704214
[TBL] [Abstract][Full Text] [Related]
38. Curing APL through PML/RARA degradation by As2O3.
Lallemand-Breitenbach V; Zhu J; Chen Z; de Thé H
Trends Mol Med; 2012 Jan; 18(1):36-42. PubMed ID: 22056243
[TBL] [Abstract][Full Text] [Related]
39. Epstein - Barr virus Latent Membrane Protein 1 suppresses reporter activity through modulation of promyelocytic leukemia protein-nuclear bodies.
Sides MD; Block GJ; Chadwick RW; Shan B; Flemington EK; Lasky JA
Virol J; 2011 Oct; 8():461. PubMed ID: 21975125
[TBL] [Abstract][Full Text] [Related]
40. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
